CCFZ533X2201 - PoC Study in de Novo Renal Transplantation: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for CCFZ533X2201 - PoC Study in de Novo Renal Transplantation (NCT02217410), a randomized phase 1, phase 2 study. The primary outcome is Efficacy as Defined by the Frequency and Severity (Banff Classification) of Treated Biopsy Proven Acute Rejection (tBPAR) Adjudicated Data - Part II.

2. Clinical Question

3. Trial Design

This was a randomized, parallel-group, open-label study in de novo renal transplant recipients. The registry lists Phase 1 and Phase 2 and reports enrollment of 59. The study title describes a 12-month evaluation. Its stated purpose included assessment of safety, tolerability, pharmacokinetics and pharmacodynamics, and efficacy of CFZ533-based regimens, including the potential to replace calcineurin inhibitors while providing a similar rate of acute rejection prophylaxis and renal function.

The treatment descriptions identify three regimens. Regimen A paired CFZ533 with the contemporary standard of care: concentration-controlled tacrolimus, mycophenolate mofetil and corticosteroids. Regimen B paired CFZ533 with mycophenolate mofetil and corticosteroids, with anti-IL2 induction. Regimen C was standard of care, consisting of concentration-controlled tacrolimus with mycophenolate mofetil and corticosteroids, also with anti-IL2 induction. Safety results are organized by groups titled CFZ533 + TAC + MMF (Part 1), CFZ533 + MMF (Part 2), and Tac + MMF (Part 2).

Randomization is intended to support comparisons between assigned groups by reducing systematic differences at allocation. An open-label design means the study was not masked to treatment assignment. The registry specifically states that an independent expert committee, blinded to therapy, adjudicated all on-cause renal biopsies for the primary endpoint. That endpoint-specific masking does not make the overall study masked.

The record gives a start date of 2015-02-05, a primary completion date of 2017-11-29, and a status of completed. It does not report the allocation ratio, details of sequence generation or concealment, or the protocol’s sample-size justification. Those details should not be inferred from the enrollment figure or from the treatment descriptions.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Study Part 1 focused on measuring the multiple-dose safety, tolerability, PK, and PD of both IV and SC CFZ533 when administered with the SoC treatment regimen. Study Part 2 investigated efficacy, safety, tolerability, PK and PD of CFZ533 in the absence of Tac.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: The PK Analysis Set included all patients with at least one available valid (i.e., not flagged for exclusion) PK concentration measurement, who received study drug and experienced no protocol deviations with relevant impact on PK data.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: The Safety Analysis Set included all patients that received at least one dose of study drug. For Part 2, all patients that received their transplant along with any patient who received study drug but had no transplant were combined.

6. Primary Endpoint

The registry lists the primary outcome as Efficacy as Defined by the Frequency and Severity (Banff Classification) of Treated Biopsy Proven Acute Rejection (tBPAR) Adjudicated Data - Part II, measured over 3, 6, 9, and 12 months.

The primary endpoint was the frequency and severity of treated biopsy-proven acute rejection, abbreviated tBPAR, assessed using the Banff classification. The registry describes the unit as events and the measure as a number. Its stated assessment times were 3, 6, 9, and 12 months. An independent expert committee blinded to therapy adjudicated all on-cause renal biopsies.

This endpoint combines whether treated, biopsy-confirmed rejection occurred with its severity classification. Biopsy confirmation and adjudication provide a defined basis for classifying suspected episodes, while the Banff scale supplies a framework for describing severity. These features make the endpoint relevant to the study’s stated aim of assessing acute rejection prophylaxis in renal transplant recipients. They do not, by themselves, establish how large or clinically important any observed difference might be.

The registry record does not report the event counts or severity distributions for the treatment groups, nor does it provide an effect estimate or confidence interval for tBPAR. As a result, the endpoint definition and assessment schedule can be described, but the comparative result cannot be interpreted from the registry record. The record also does not report how recurrent events were handled in the statistical analysis or how the measurements across the assessment times were combined.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes a randomized parallel-group study. In general, random allocation is used to make treatment groups comparable in expectation at the start of a trial. That benefit depends on how allocation was implemented and on what happens after assignment; the registry record does not report all the implementation details. Parallel-group design means assigned regimens are compared across groups rather than through a planned sequence of treatments within each participant.

What does open-label mean for interpretation?

Open-label means the study was not masked to treatment assignment. In general, awareness of assignment can influence care, reporting, or assessment, depending on the outcome and study procedures. The record describes a specific protection for the primary endpoint: an independent expert committee blinded to therapy adjudicated all on-cause renal biopsies. This is relevant to the adjudication of biopsies, but it does not establish that participants or treating clinicians were masked. The registry does not report further procedures for limiting bias in outcome collection or assessment.

How should the primary endpoint be understood?

The endpoint is a count-based measure of treated biopsy-proven acute rejection, with severity classified using the Banff scale. It was assessed at 3, 6, 9, and 12 months. General statistical interpretation depends on the exact analysis: an event count, the proportion of participants with an event, and time to first event answer different questions. The registry record gives the unit as events, but does not report the statistical model or explain whether the primary analysis concerned recurrent events, participants with at least one event, or another summary. It is therefore not appropriate to attribute a particular analysis method to this endpoint.

Repeated assessment times can also create analytical choices. General approaches may treat each time separately, model change over time, or define a cumulative outcome over a specified period. These approaches can yield different summaries and have different assumptions. The registry record does not report which approach was used, whether results were adjusted for baseline factors, or how correlation among repeated observations was handled. No such details can be inferred from the assessment schedule alone.

What do estimates and confidence intervals convey?

In general, an effect estimate expresses the size and direction of a comparison on a chosen scale. A confidence interval describes the precision of that estimate under the assumptions of the analysis: a wider interval indicates less precision, while a narrower interval indicates more precision. A confidence interval is not a guarantee that the true effect lies inside its limits. The registry record does not report a primary effect estimate or confidence interval for tBPAR, so neither the scale nor the precision of the primary comparison can be evaluated.

In general, a p-value measures how incompatible observed data are with a specified null model, assuming the model and analysis conditions hold. It is not a measure of the probability that a treatment is effective, nor does it describe the size of an effect. The registry record does not report a primary p-value or enough analysis detail to determine how any such value would have been calculated. No significance claim should be inferred from the endpoint description or the study’s completion status.

What can planning calculations say?

The stated sample-size assumptions describe planning illustrations based on the observed effect, not the trial’s own design. They specify a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation, with the effect to detect set as a stated fraction of the observed effect. For time-to-event tables, the planning quantity is the total number of events using the Schoenfeld approach; other planning quantities are participants per arm. Such calculations are illustrative planning aids, not observed power and not evidence that the completed trial was designed to detect those effects. The registry record does not report the trial’s own sample-size justification.

General sample-size calculations depend on assumptions about the effect to detect, variability or event frequency, allocation, significance level and desired power. Changing those assumptions changes the resulting planning requirement. Since the primary endpoint has multiple categories or time points and is not reduced to one comparison in the registry record, a single observed effect for a single comparison is not available for a direct interpretation. No sample-size value or power value should be treated as an observed trial result.

10. Multiplicity, Missing Data and Analysis Populations

The primary endpoint includes frequency and severity of tBPAR and is assessed at 3, 6, 9, and 12 months. The registry record also lists 11 outcome measures and 4 analyses. Multiple outcomes, time points, treatment comparisons or analyses can create multiplicity: when many statistical questions are considered, the chance of at least one apparently notable result can increase. General methods for addressing multiplicity include prespecifying a primary comparison, using a testing hierarchy, or adjusting inference across a family of tests. The registry record does not report whether any such procedure was planned or used.

The record does not report the primary outcome’s results or its statistical analysis plan. In particular, it does not state how the different assessment times or severity categories were combined, which treatment contrast was primary, whether the analysis was adjusted, or how repeated events were handled. The record’s note that the endpoint has several categories or time points and is not reduced to one comparison means that a single effect estimate should not be assumed.

The PD analysis set is defined as patients in the Full Analysis set with available PD data and no protocol deviations with relevant impact on PD data. That description identifies a population for pharmacodynamic analysis; it does not establish the population used for every efficacy or safety analysis. The registry record does not report the primary endpoint analysis population or how missing biopsy, follow-up or endpoint data were handled. It also does not report whether sensitivity analyses were conducted to examine the effect of missing data or analysis-population choices.

These omissions limit assessment of the inferential framework. They do not demonstrate that the study failed to prespecify methods; they mean those methods are not reported in the registry record. Without the planned comparison, missing-data rules and multiplicity approach, readers cannot fully evaluate how the primary inference was constructed.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 2% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: vomiting (28.6%), pyelonephritis (16.7%), kidney transplant rejection (14.7%), photophobia (14.3%), vision blurred (14.3%).

The registry reports serious adverse-event counts by safety group, alongside the number at risk. For CFZ533 + TAC + MMF (Part 1), 4 participants were affected among 7 at risk. For CFZ533 + MMF (Part 2), 21 were affected among 34 at risk. For Tac + MMF (Part 2), 12 were affected among 18 at risk. The total is 37 affected among 59 at risk. Deaths are reported as 0 in each listed group and in the total.

For other adverse events, the corresponding reported counts are 7 among 7 at risk, 33 among 34 at risk, and 18 among 18 at risk; the total is 58 among 59 at risk. These counts describe participants recorded as affected in the registry. They do not state how many events each affected participant experienced, how long each participant was observed, or how the events were distributed over time. The record does not report a comparative statistical analysis of these counts.

The registry lists serious-event terms with percentages, including vomiting at 28.6%, pyelonephritis at 16.7%, kidney transplant rejection at 14.7%, photophobia at 14.3%, vision blurred at 14.3%, and abdominal pain at 14.3%. The record excerpt does not specify the denominator or group attribution for each listed percentage, so these values should not be assigned to a treatment group or interpreted as comparative risks.

These safety summaries are descriptive. Differences in group size and follow-up can affect raw counts, and the registry record does not supply enough information to adjust for those features. The figures should not be read as proof that one regimen is safer or less safe than another.

12. What the Result Does, and Does Not, Mean

The record documents a randomized study of CFZ533-containing regimens in de novo renal transplant recipients, including a tacrolimus-based standard-of-care comparator. It defines the primary endpoint as frequency and severity of treated biopsy-proven acute rejection, classified using the Banff scale and assessed at 3, 6, 9, and 12 months. It also documents that an independent expert committee blinded to therapy adjudicated all on-cause renal biopsies.

Those design and endpoint details explain what the study sought to evaluate; they do not reveal what the comparison found. The registry record does not report the primary tBPAR event counts, severity results, treatment effect, confidence interval or p-value. It is therefore not possible from this record to determine the direction or size of an efficacy difference, or how precisely it was estimated. The lack of a reported result should not be interpreted as evidence of no difference.

The safety information does show recorded counts of participants affected by serious and other adverse events, and reports no deaths in the listed groups. These are not complete comparative safety estimates: the record does not provide a statistical comparison, detailed observation time, or the event-level information needed to describe recurrence or timing. The listed serious-event percentages also lack group attribution in the record excerpt.

The study’s stated aim included examining whether CFZ533 could replace calcineurin inhibitors while providing a similar rate of acute rejection prophylaxis and renal function. The aim is not itself a finding. The registry record does not report enough primary endpoint results to establish similarity, superiority, non-inferiority or equivalence. Such claims require defined comparisons and results interpreted against an appropriate analysis plan and margin where applicable; those details are not reported in the registry record.

Accordingly, the most defensible reading is descriptive: the record identifies the study population, treatment strategies, design, endpoint definition and selected safety counts. It does not provide the outcome evidence needed to judge the relative efficacy or safety of the regimens.

13. Why This Trial Matters Statistically

This trial raises statistical questions that are common in clinical research, particularly when an endpoint has several assessment times and includes both event occurrence and severity. A clear endpoint definition is essential, but interpretation also depends on how the analysis turns those components into a comparison. The registry record gives the assessment schedule and Banff classification but does not report how these elements were analyzed or combined.

The design also illustrates the distinction between masking across a trial and blinding at a specific assessment stage. The study was open-label, while an independent expert committee blinded to therapy adjudicated on-cause renal biopsies. That distinction matters: an endpoint-specific safeguard can strengthen consistency in classification without changing the open-label status of the broader study.

Another statistical issue is the difference between a study’s stated objective and a result demonstrating that objective. The stated purpose included considering CFZ533 as a possible replacement for calcineurin inhibitors while maintaining a similar rate of acute rejection prophylaxis and renal function. Demonstrating similarity would require an appropriate estimand, a defined margin and reported comparative results. The registry record does not report those details or the primary endpoint result, so the objective cannot be treated as an established conclusion.

The study also highlights why safety counts need context. Raw counts describe recorded participants affected, but they do not by themselves account for differences in group size, observation time or event recurrence. The record supplies group-level counts but not a comparative safety analysis. This limits the kinds of conclusions that can be drawn from them.

Finally, the record distinguishes the PD analysis set from the overall enrollment, while leaving the primary efficacy analysis population and missing-data methods unreported. Statistical interpretation depends not only on the randomized design but also on which observations enter each analysis and how unavailable measurements are handled. Reporting these choices alongside effect estimates and uncertainty would be necessary for a fuller appraisal.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation for interpreting this trial from the registry record is the absence of the primary endpoint results. Although tBPAR is defined and its assessment times are stated, there are no group-specific event counts, severity distributions, treatment-effect estimates or confidence intervals. The primary efficacy question therefore cannot be answered from the record.

The registry record does not report the statistical analysis plan, the primary contrast, or how event frequency and severity across 3, 6, 9, and 12 months were handled. It also does not state whether repeated events were counted, how outcomes at multiple times were combined, or whether any adjustment for baseline variables was used. The presence of multiple outcome measures and analyses makes the missing multiplicity procedures relevant, but the record does not establish whether adjustment was or was not used.

The PD analysis set is described, but the record does not identify the population used for the primary efficacy analysis. It does not report missing-data procedures, participant flow by analysis population, or sensitivity analyses. Consequently, the effect of missing endpoint information or population selection cannot be assessed.

The design was open-label. The record reports blinded adjudication of all on-cause renal biopsies by an independent expert committee, but does not describe other safeguards or the procedures used to ensure consistent outcome ascertainment. Randomization is reported, but allocation ratio and further details of allocation procedures are not reported.

Safety reporting is also limited for comparative interpretation. Group counts are available, but the record does not provide event timing, duration of follow-up by group, recurrent-event detail, or a comparative statistical analysis. It lists serious-event percentages without specifying their denominator or group attribution in the record excerpt. Finally, the record does not report the trial’s own sample-size justification. These limitations concern what is documented in the registry record and do not establish that unreported procedures or analyses were not conducted.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: CCFZ533X2201 - PoC Study in de Novo Renal Transplantation — NCT02217410.
• Registry record last updated 2021-09-28; status last verified 2021-09.
• Results first posted 2018-12-21.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record describes NCT02217410, titled CCFZ533X2201 - PoC Study in de Novo Renal Transplantation. It reports a randomized, open-label, parallel-group Phase 1 and Phase 2 study with enrollment of 59, a start date of 2015-02-05, a primary completion date of 2017-11-29, and completed status.

The study evaluated CFZ533-containing regimens alongside a tacrolimus-based standard-of-care regimen in de novo renal transplant recipients. The primary endpoint was the frequency and severity of treated biopsy-proven acute rejection, using Banff classification, at 3, 6, 9, and 12 months. An independent expert committee blinded to therapy adjudicated all on-cause renal biopsies.

The registry record reports safety counts, but does not report the primary endpoint results, a comparative effect estimate, confidence interval, or the statistical analysis methods needed to interpret the efficacy comparison. The PD analysis set is defined, but the primary efficacy analysis population and missing-data methods are not reported.